Alzheimer’s and brain imaging
Executive Summary
The role of brain imaging as an outcome measure in Phase III Alzheimer's Disease trials will be discussed at a joint meeting of FDA's Peripheral & Central Nervous System Drugs and Medical Imaging Drugs Advisory Committees Nov. 18. On Nov. 19, the committees will review Down State Medical's positron emission tomography agent F18 fluoro-D-glucose for imaging in Alzheimer's Disease. The meeting will take place at the Holiday Inn, Gaithersburg, Md...
You may also be interested in...
Down State Medical F18 FDG review cancelled
A Nov. 19 review of Down State Medical's positron emission tomography agent F18 fluoro-D-glucose (FDG) for the diagnosis and/or identification of Alzheimer's disease progression has been cancelled. FDA's Peripheral & Central Nervous System Drugs Committee still will discuss the use of Alzheimer's brain imaging as a surrogate endpoint in clinical trials on Nov. 18 (1"The Pink Sheet" Sept. 30, In Brief)...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.